Selected EMA news, February 2025
New medicines recommended for approval
- Dyrupeg (pegfilgrastim) – biosimilar
Treatment to shorten the duration of neutropenia and help prevent febrile neutropenia after cytotoxic chemotherapy - Eltrombopag Accord (eltrombopag) – generic
Treatment of primary immune thrombocytopenia and thrombocytopenia associated with chronic hepatitis C
New information on approved medicines
- Breyanzi (lisocabtagene maraleucel) – new indication
Treatment of follicular lymphoma and large B-cell lymphoma (types of blood cancer)
Supply shortages
- Eldisine (vindesine)
Treatment of different types of blood cancers, such as acute lymphoblastic leukemia and chemotherapy-refractory lymphoma, as well as certain solid tumors